This is a $7,133,828 firm-fixed-price contract awarded by the Centers for Disease Control and Prevention (CDC) to Westat, Inc. to develop and evaluate innovative methods to estimate the secondary attack rate of respiratory virus-associated illness. The contract has no set-aside designation. Westat is a for-profit professional services firm that provides a range of research, data collection, and program evaluation services to federal agencies, including the Department of Health and Human Services. This contract contributes to the CDC's work in public health surveillance and is part of Westat's portfolio of indefinite delivery/indefinite quantity (IDIQ) contracts with various federal agencies.
Generated 6/25/24, 2:09 PM